

NDA 19-676/S-016

Genentech, Inc.
Attention: Robert L. Garnick, Ph.D.
Vice President, Regulatory Affairs
1 DNA Way
South San Francisco, CA 94080-4990

Dear Dr. Garnick:

Please refer to your supplemental new drug application dated June 11, 1999, received June 14, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Nutropin (somatropin [rDNA origin] for injection).

We acknowledge receipt of your submissions dated August 5 and November 19, 1999, and March 27 and 30, and April 11, 2000.

This supplemental new drug application provides for the addition of a higher dose of Nutropin (somatropin [rDNA origin] for injection) for pubertal patients (pubertal dose ≤ 0.7 mg/kg/wk) to the **DOSAGE AND ADMINISTRATION** section of the product insert.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

You are not required to complete a pediatric assessment for this application because it is not covered by the Pediatric Rule (21 CFR 314.55(a)).

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted April 11, 2000).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 19-676/S-016." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your Phase 4 commitments specified in your submission dated March 30, 2000. These commitments, along with any completion dates agreed upon, are listed below.

Genentech will provide the following updates for the four-year period following the commercial launch of the pubertal dose regimen:

1. NDA Annual Reports – You will create a subsection of the National Comparative Growth Study update section and use this to report the number of patients receiving a dose greater than or equal to 0.4 mg/kg/week. Further, you will discuss any other information available relevant to these patients.
2. Periodic Safety Reports – You will create a section that describes the spontaneous adverse event reports and the safety information from National Comparative Growth Study for patients receiving greater than or equal to 0.4 mg/kg/week dosing. This section will discuss the safety profile of these patients as compared to patients receiving doses of less than 0.4 mg/kg/week (excluding Turner Syndrome and Chronic Renal Insufficiency patients).
3. Expedited Adverse Event Reports – For any relevant expedited adverse event reports, at the beginning of the narrative in section B-5, “Describe Event or Problem,” of the Med Watch Form 3500A, you will use surrounding asterisks to emphasize that the patient was being dosed at greater than or equal to 0.4 mg/kg/week. You will also include this information in the cover letter that accompanies each of these reports, again highlighted in such a manner as to draw immediate attention to the fact.

Data and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.81(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Crystal King, P.D., M.G.A., Regulatory Project Manager, at (301) 827-6423.

Sincerely yours,

John K. Jenkins, M.D.
Acting Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research